BioSapien develops the DiagX, a modular diagnostic device that integrates AI for multi-parameter analysis of biological signals. This platform offers high-precision, real-time data processing for enhanced diagnostic accuracy and operational efficiency in healthcare settings.
Funding
Funding not disclosed
Founders
Product
Problem
Current medical diagnostic technologies often require specialized equipment and can be limited in their ability to perform multiple analyses simultaneously, impacting diagnostic efficiency and accessibility. This can lead to delays in clinical decision-making and hinder the early detection of various conditions.
Solution
BioSapien is developing the DiagX, a modular diagnostic device that integrates biomedical engineering with artificial intelligence to provide multi-parameter analysis of biological signals. The platform is designed for high-precision, real-time data processing, enabling enhanced diagnostic accuracy and operational efficiency. Its advanced architecture supports a range of examinations, facilitating improved clinical decision-making through comprehensive data insights. The device prioritizes secure data transmission and adheres to stringent data protection standards.
Target Audience
The primary target audience includes healthcare professionals and institutions seeking advanced, versatile diagnostic tools to improve patient care and streamline clinical workflows.
Features
- Modular architecture with interchangeable components for customizable diagnostic applications, including ECG, EEG, and pulse oximetry.
- High-performance microcontrollers operating at 240MHz for real-time biological data analysis.
- Integrated BLE 5.0 and Wi-Fi 802.11 for seamless wireless connectivity and remote monitoring capabilities.
- Advanced signal converters for high-resolution biopotential acquisition.
- Robust data security protocols, including end-to-end encryption, to ensure compliance with data privacy regulations.
- AI-driven analytics for enhanced diagnostic precision and trend identification.